Spyre Therapeutics
SYRE
71 hedge funds and large institutions have $154M invested in Spyre Therapeutics in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 24 increasing their positions, 22 reducing their positions, and 11 closing their positions.
1,800% more call options, than puts
Call options by funds: $19K | Put options by funds: $1K
13% more capital invested
Capital invested by funds: $137M → $154M (+$17.4M)
9% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 22
0% more ownership
Funds ownership: 2.78% → 2.78% (+0%)
8% less funds holding
Funds holding: 77 → 71 (-6)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$5.45M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
+$1.18M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$1.11M |
| 4 |
AG
Artal Group
Luxembourg
|
+$1.02M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$527K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.52M |
| 2 |
FI
Fosun International
Hong Kong,
China
|
-$1.31M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.28M |
| 4 |
Millennium Management
New York
|
-$520K |
| 5 |
Man Group
London,
United Kingdom
|
-$393K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Two Sigma Investments
New York
| – | -$339K | -1,978 | Closed |
|
77
Jacobs Levy Equity Management
Florham Park,
New Jersey
| – | -$328K | -1,914 | Closed |
|
78
Citadel Advisors
Miami,
Florida
| – | -$203K | -1,189 | Closed |
|
|
LI
79
Leap Investments
Chicago,
Illinois
| – | -$114K | -664 | Closed |
|
|
SAM
80
Sectoral Asset Management
Montreal,
Quebec, Canada
| – | -$89K | -518 | Closed |
|
81
Ohio Public Employees Retirement System (OPERS)
Columbus,
Ohio
| – | -$27K | -156 | Closed |
|
|
RBC
82
Roble Belko & Company
Sewickley,
Pennsylvania
| – | -$1K | -4 | Closed |
|
SYRE Hedge Fund Activity: Q3 2019 in Review
71 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q3 2019, worth a combined $154M — up 13% from $137M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of SYRE and 6 opened new positions — a net loss of 5 holders — while 22 trimmed existing stakes and 24 added.
The largest buyer was OrbiMed, adding an estimated $5.45M. The largest seller was Assenagon Asset Management, cutting an estimated $1.52M.
- 71 institutional investors held Spyre Therapeutics (SYRE) as of Q3 2019, down from 77 in Q2 2019.
- Funds reported $154M of Spyre Therapeutics stock for Q3 2019, up 13% quarter-over-quarter.
- 6 funds opened new Spyre Therapeutics positions in Q3 2019 and 11 closed out, a net change of -5 holders.
- The largest Spyre Therapeutics buyer in Q3 2019 was OrbiMed, an estimated $5.45M added.
- The largest Spyre Therapeutics seller in Q3 2019 was Assenagon Asset Management, an estimated $1.52M sold.
Based on aggregated 13F filings for Q3 2019.